Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101
October 19, 2015 at 07:04 AM EDT
Cerulean Pharma Inc. (NASDAQ: CERU), a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced that the ...
